SCHEMBL14920105

SCHEMBL14920105

COC(=O)c1ccc(C(C)(C)O[SiH2]C(C)(C)C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
ALDH1A1 P00352 1/20 0.47
CA1 P00915 4/20 0.47
CA2 P00918 4/20 0.47
TDP1 Q9NUW8 1/20 0.47
CA12 O43570 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
TSHR P16473 1/20 0.44
NOTUM Q6P988 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
ATM Q13315 1/20 0.41
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5449161 0.85 PTPN11 (0.46) MAPTALDH1A1CA1CA2CA12
SCHEMBL5177242 0.80 CA1 (0.55) MAPTALDH1A1CA1CA2TDP1
SCHEMBL22334817 0.79 CA1 (0.53) MAPTALDH1A1CA1CA2TDP1
SCHEMBL9521933 0.77 MAPK1 (0.50) MAPTALDH1A1CA1CA2TDP1
SCHEMBL2890249 0.76 CA1 (0.59) MAPTALDH1A1CA1CA2TDP1
SCHEMBL677961 0.76 CA1 (0.59) MAPTALDH1A1CA1CA2TDP1
SCHEMBL592406 0.76 CA1 (0.68) MAPTALDH1A1CA1CA2TDP1
SCHEMBL1367395 0.76 NOTUM (0.47) MAPTALDH1A1CA1CA2TDP1
SCHEMBL505475 0.76 ALDH1A1 (0.35) MAPTALDH1A1CA1CA2CA12
SCHEMBL5270913 0.74 ESR1 (0.48) ALDH1A1TSHRMEN1KMT2AKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9145354-B2 Pharmaceutical compounds ASTEX THERAPEUTICS LIMITED (GB) 2015-09-29 US disclosed
US-20150051199-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2015-02-19 US disclosed
EP-2773615-A1 PHARMACEUTICAL COMPOUNDS Astex Therapeutics Limited (GB) 2014-09-10 EP disclosed
WO-2013064543-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2013-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051199-A1 PHARMACEUTICAL COMPOUNDS NR1H4, HAVCR2, NR1H3 MAPT 2856/4885ALDH1A1 3105/4885CA1 2350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.